Summary & Overview
CPT 0569U: Guardant Reveal™ ctDNA Methylation NGS Assay
CPT code 0569U designates Guardant Reveal™, a proprietary circulating tumor DNA (ctDNA) next‑generation sequencing (NGS) assay that profiles over 20,000 DNA regions for abnormal methylation patterns linked to solid tumors and may report a tumor fraction. This PLA code is specific to a single manufacturer's test and reflects the growing role of blood‑based molecular diagnostics in oncology screening, surveillance, and personalized care. Nationally, such laboratory innovation affects payer coverage decisions, laboratory billing practices, and access to minimally invasive tumor detection tools.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise review of coverage and reimbursement benchmarks, payer policy considerations, clinical context for use of ctDNA methylation assays, and implications for billing and coding workflows. Readers will find a clear explanation of the test's clinical purpose and service setting, an overview of common modifiers used with laboratory services, and a summary of available payer approaches. Data not provided in the input are identified as unavailable. The content is intended for national stakeholders seeking a focused briefing on billing, clinical utility, and payer handling of CPT code 0569U.
Billing Code Overview
CPT code 0569U is a Proprietary Laboratory Analyses (PLA) code reported only for Guardant Reveal™ from Guardant Health Inc. The test uses next–generation sequencing (NGS) to examine more than 20,000 regions of DNA for abnormal methylation patterns associated with solid tumors. It analyzes circulating tumor DNA (ctDNA) in a blood sample to detect the presence or absence of tumor‑derived genetic material. When appropriate, results include a tumor fraction value.
Service type: Laboratory — circulating tumor DNA methylation NGS assay
Typical site of service: Outpatient laboratory or clinical laboratory setting using a blood specimen (phlebotomy)
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a history of resected stage II colon adenocarcinoma presents for post-treatment surveillance. The treating oncologist orders a blood-based circulating tumor DNA (ctDNA) assay to evaluate for molecular residual disease and early recurrence. A peripheral blood draw is collected in the outpatient oncology clinic and sent to the manufacturer's laboratory. The Guardant Reveal™ test (0569U) uses next-generation sequencing to detect abnormal methylation patterns across >20,000 genomic regions and reports presence/absence of tumor-derived ctDNA and, when detectable, a tumor fraction value. Typical workflow steps: specimen collection (phlebotomy), specimen labeling and courier shipment under laboratory chain-of-custody, laboratory accessioning and sample processing, NGS-based methylation and ctDNA analysis, result interpretation by the performing laboratory, and transmission of a final report to the ordering oncologist. Typical sites of service include outpatient oncology clinics, ambulatory infusion centers, and independent phlebotomy or reference laboratory draw sites. Common clinical indications include surveillance after curative-intent therapy, evaluation for minimal residual disease, and adjunctive assessment for recurrence risk stratification.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the laboratory or performing provider documents and bills for markedly increased laboratory work or interpretive effort beyond typical requirements for the assay (rare for PLA tests). |
52 | Reduced services | Use if testing is partially performed or a reduced-scope analytic run is completed due to limited specimen volume or partial processing. |
53 | Discontinued procedure | Use if the specimen collection or testing procedure is terminated prior to completion for valid clinical reasons (e.g., compromised specimen) and the lab bills for preparatory work. |
59 | Distinct procedural service | Use when this assay is billed separately and is distinct from other laboratory services on the same day (note: sequencing assays are usually distinct; 59 may be used if payer guidance requires). |
90 | Reference (outside) laboratory | Use when the performing laboratory billed by an outside reference lab performs the test for the ordering provider. |
91 | Repeat clinical diagnostic laboratory test | Use for immediate repeat testing on the same sample or patient when clinically indicated (e.g., assay failure and repeat run). |
LT | Left side | Not typically applicable to blood-based assays; included for completeness and typically not used for this code. |
RT | Right side | Not typically applicable to blood-based assays; typically not used for this code. |
QV | Investigational device exemption (example placeholder—note: QV is not an official CMS modifier) | Data not applicable; do not use unless payer specifically instructs (CMS-standardized modifiers only should be used). |
CP | Diagnostic laboratory panel component | Use when billing requires a panel component modifier to indicate part of a multi-part test (payer dependent). |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 363L00000X | Clinical Laboratory | Laboratories performing high-complexity molecular testing, including NGS-based ctDNA and methylation assays. |
| 207R00000X | Medical Oncology | Oncologists who order ctDNA MRD testing for surveillance and treatment planning. |
| 208000000X | Hematology/Oncology | Combined specialty clinicians who manage solid tumor surveillance and interpret ctDNA results. |
| 207P00000X | Pathology | Molecular pathology laboratories and pathologists overseeing NGS assay validation and interpretation. |
| 207L00000X | Diagnostic Radiology (molecular diagnostic oversight) | Occasionally involved in multidisciplinary interpretation alongside imaging surveillance results. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
C18.9 | Malignant neoplasm of colon, unspecified | Common primary tumor site for ctDNA minimal residual disease surveillance using Guardant Reveal™. |
C50.919 | Malignant neoplasm of unspecified site of right female breast | Breast cancer is a solid tumor indication where ctDNA methylation assays may be applied for recurrence monitoring. |
C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung | Lung cancer patients may undergo ctDNA testing for surveillance or recurrence detection. |
C61 | Malignant neoplasm of prostate | Prostate cancer surveillance and molecular assessments can include blood-based assays in certain contexts. |
Z08 | Encounter for follow-up examination after completed treatment for malignant neoplasm | Typical encounter code when ordering ctDNA for post-treatment surveillance. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
36415 | Collection of venous blood by venipuncture | Phlebotomy for obtaining the blood specimen required for the Guardant Reveal™ ctDNA test. |
81000 | Urinalysis, by dipstick or tablet reagent | Sometimes ordered concurrently for general clinical assessment but not directly related to ctDNA testing. |
0001U | (Example PLA) Molecular pathology procedure, analytical test (placeholder) | Other Proprietary Laboratory Analyses may be ordered alongside or as alternative molecular assays; use depends on clinical question and payer coverage. |
G0480 | Drug screen, presumptive, any number of tests | Occasionally performed in comprehensive workups but not routinely linked to ctDNA testing. |
88381 | Consultation and report on tissue-based molecular pathology procedures | If tissue molecular testing is performed in parallel for tumor profiling, pathology consult codes document interpretation and correlation with ctDNA results. |